# Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

> **NCT04901702** · PHASE1,PHASE2 · RECRUITING · sponsor: **St. Jude Children's Research Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Recurrent Solid Tumor
- Recurrent Ewing Sarcoma
- Recurrent Hepatoblastoma
- Recurrent Malignant Germ Cell Tumor
- Recurrent Malignant Solid Neoplasm
- Recurrent Neuroblastoma
- Recurrent Osteosarcoma
- Recurrent Peripheral Primitive Neuroectodermal Tumor
- Recurrent Rhabdoid Tumor
- Recurrent Rhabdomyosarcoma
- Recurrent Soft Tissue Sarcoma
- Recurrent Wilms Tumor
- Refractory Ewing Sarcoma
- Refractory Hepatoblastoma
- Refractory Malignant Germ Cell Tumor
- Refractory Malignant Solid Neoplasm
- Refractory Neuroblastoma
- Refractory Osteosarcoma
- Refractory Peripheral Primitive Neuroectodermal Tumor
- Refractory Rhabdoid Tumor
- Refractory Rhabdomyosarcoma
- Refractory Soft Tissue Sarcoma

## Interventions

- **DRUG:** Onivyde
- **DRUG:** Talazoparib
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT04901702
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-06-09
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04901702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04901702, "Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT04901702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*